

John M Murray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2066622/publications.pdf>

Version: 2024-02-01

102
papers

3,346
citations

136740

32
h-index

155451

55
g-index

104
all docs

104
docs citations

104
times ranked

3915
citing authors

#	ARTICLE	IF	CITATIONS
1	A General Framework for Fractional Order Compartment Models. <i>SIAM Review</i> , 2021, 63, 375-392.	4.2	6
2	NGlyAlign: an automated library building tool to align highly divergent HIV envelope sequences. <i>BMC Bioinformatics</i> , 2021, 22, 54.	1.2	0
3	Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic <sc>HIV</sc> infection and active <sc>HIV</sc> control. <i>International Journal of Cancer</i> , 2021, 149, 297-306.	2.3	5
4	High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities. <i>Microorganisms</i> , 2021, 9, 968.	1.6	5
5	Variability in molecular characteristics of Hepatitis E virus quasispecies could modify viral surface properties and transmission. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1078-1090.	1.0	1
6	Birth-cohort estimates of smoking initiation and prevalence in 20th century Australia: Synthesis of data from 33 surveys and 385,810 participants. <i>PLoS ONE</i> , 2021, 16, e0250824.	1.1	3
7	Dynamics of latent HIV under clonal expansion. <i>PLoS Pathogens</i> , 2021, 17, e1010165.	2.1	1
8	The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling study. <i>PLoS ONE</i> , 2020, 15, e0231388.	1.1	20
9	High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort. <i>BMC Gastroenterology</i> , 2020, 20, 24.	0.8	20
10	Mutational networks of escape from transmitted HIV-1 infection. <i>PLoS ONE</i> , 2020, 15, e0243391.	1.1	1
11	Title is missing!. , 2020, 15, e0231388.		0
12	Title is missing!. , 2020, 15, e0231388.		0
13	Title is missing!. , 2020, 15, e0231388.		0
14	Title is missing!. , 2020, 15, e0231388.		0
15	Treatment as prevention enrolling at least 75% of individuals on ART will be needed to significantly reduce HIV prevalence in a HIV cohort. <i>Journal of Clinical Virology</i> , 2019, 120, 27-32.	1.6	0
16	Analysis and dissociation of anti-HIV effects of shRNA to CCR5 and the fusion inhibitor C46. <i>Journal of Gene Medicine</i> , 2018, 20, e3006.	1.4	9
17	Special Issue "Mathematical Modeling of Viral Infections". <i>Viruses</i> , 2018, 10, 303.	1.5	2
18	Latent HIV dynamics and implications for sustained viral suppression in the absence of antiretroviral therapy. <i>Journal of Virus Eradication</i> , 2018, 4, 91-98.	0.3	4

#	ARTICLE	IF	CITATIONS
19	Fractional Order Compartment Models. <i>SIAM Journal on Applied Mathematics</i> , 2017, 77, 430-446.	0.8	35
20	Roadmap to control HBV and HDV epidemics in China. <i>Journal of Theoretical Biology</i> , 2017, 423, 41-52.	0.8	12
21	Examining the role of store design on consumers'™ cross-sectional perceptions of retail brand loyalty. <i>Journal of Retailing and Consumer Services</i> , 2017, 38, 147-156.	5.3	34
22	Drivers of supplier-customer relationship profitability in China: Assessing International Joint Ventures versus State Owned Enterprises. <i>Industrial Marketing Management</i> , 2017, 66, 29-41.	3.7	14
23	Internal brand identification as metamorphic glue in the internal branding process within a retailer network. <i>International Review of Retail, Distribution and Consumer Research</i> , 2017, 27, 533-551.	1.3	1
24	Differentiating founder and chronic HIV envelope sequences. <i>PLoS ONE</i> , 2017, 12, e0171572.	1.1	3
25	HIV dynamics linked to memory CD4+ T cell homeostasis. <i>PLoS ONE</i> , 2017, 12, e0186101.	1.1	11
26	Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy. <i>Journal of Viral Hepatitis</i> , 2016, 23, 387-398.	1.0	22
27	Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China. <i>Clinical Drug Investigation</i> , 2016, 36, 637-648.	1.1	6
28	Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication. <i>Theoretical Population Biology</i> , 2016, 112, 60-69.	0.5	7
29	Dynamics of in vivo hepatitis D virus infection. <i>Journal of Theoretical Biology</i> , 2016, 398, 9-19.	0.8	5
30	Variability in long-term hepatitis B virus dynamics under antiviral therapy. <i>Journal of Theoretical Biology</i> , 2016, 391, 74-80.	0.8	8
31	The unrooted set covering connected subgraph problem differentiating between HIV envelope sequences. <i>European Journal of Operational Research</i> , 2016, 248, 668-680.	3.5	5
32	Modelling the Impact of Cell-To-Cell Transmission in Hepatitis B Virus. <i>PLoS ONE</i> , 2016, 11, e0161978.	1.1	29
33	Reply to "does chronic hepatitis E virus infection exist in immunocompetent patients?". <i>Hepatology</i> , 2015, 61, 2117-2117.	3.6	2
34	Effect of interferon-α therapy on hepatitis D virus. <i>Hepatology</i> , 2015, 61, 2117-2118.	3.6	4
35	Predicting First Traversal Times for Virions and Nanoparticles in Mucus with Slowed Diffusion. <i>Biophysical Journal</i> , 2015, 109, 164-172.	0.2	13
36	Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. <i>Aids</i> , 2015, 29, 911-919.	1.0	37

#	ARTICLE	IF	CITATIONS
37	In silico single cell dynamics of hepatitis B virus infection and clearance. <i>Journal of Theoretical Biology</i> , 2015, 366, 91-102.	0.8	39
38	High prevalence and incidence of HIV, sexually transmissible infections and penile foreskin cutting among sexual health clinic attendees in Papua New Guinea. <i>Sexual Health</i> , 2014, 11, 58.	0.4	16
39	A Quantitative Comparison of Anti-HIV Gene Therapy Delivered to Hematopoietic Stem Cells versus CD4+ T Cells. <i>PLoS Computational Biology</i> , 2014, 10, e1003681.	1.5	15
40	HIV DNA Subspecies Persist in both Activated and Resting Memory CD4 ⁺ T Cells during Antiretroviral Therapy. <i>Journal of Virology</i> , 2014, 88, 3516-3526.	1.5	76
41	Impact of Male Circumcision on the HIV Epidemic in Papua New Guinea: A Country with Extensive Foreskin Cutting Practices. <i>PLoS ONE</i> , 2014, 9, e104531.	1.1	5
42	The Impact of Vaccination and Antiviral Therapy on Hepatitis B and Hepatitis D Epidemiology. <i>PLoS ONE</i> , 2014, 9, e110143.	1.1	46
43	Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization. <i>Journal of Infectious Diseases</i> , 2013, 207, 1306-1315.	1.9	9
44	Turing Patterns from Dynamics of Early HIV Infection. <i>Bulletin of Mathematical Biology</i> , 2013, 75, 774-795.	0.9	59
45	Explaining the Determinants of First Phase HIV Decay Dynamics through the Effects of Stage-dependent Drug Action. <i>PLoS Computational Biology</i> , 2013, 9, e1002971.	1.5	15
46	The Majority of HIV Type 1 DNA in Circulating CD4 ⁺ T Lymphocytes Is Present in Non-Gut-Homing Resting Memory CD4 ⁺ T Cells. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1330-1339.	0.5	18
47	Short Communication: HIV Blips While on Antiretroviral Therapy Can Indicate Consistently Detectable Viral Levels Due to Assay Underreporting. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1621-1625.	0.5	7
48	HIV Treatment as Prevention in a Developed Country Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 409-416.	0.9	3
49	Genotype 1 Hepatitis C Virus Envelope Features That Determine Antiviral Response Assessed through Optimal Covariance Networks. <i>PLoS ONE</i> , 2013, 8, e67254.	1.1	8
50	Clinical impact of hepatitis B and C virus envelope glycoproteins. <i>World Journal of Gastroenterology</i> , 2013, 19, 654.	1.4	13
51	Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. <i>Aids</i> , 2012, 26, 543-550.	1.0	62
52	T-lymphocyte perturbation following large-scale apheresis and hematopoietic stem cell transplantation in HIV-infected individuals. <i>Clinical Immunology</i> , 2012, 144, 159-171.	1.4	11
53	Application of a case-control study design to investigate genotypic signatures of HIV-1 transmission. <i>Retrovirology</i> , 2012, 9, 54.	0.9	5
54	Gendered futures, constrained choices: undergraduate perceptions of work and family. <i>Journal of Population Research</i> , 2012, 29, 315-328.	0.6	5

#	ARTICLE	IF	CITATIONS
55	Modelling hepatitis C virus infection and the development of hepatocellular carcinoma. <i>Journal of Theoretical Biology</i> , 2012, 305, 24-29.	0.8	10
56	Stochastic Model of In-Vivo X4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc. <i>PLoS ONE</i> , 2012, 7, e38755.	1.1	7
57	Findings regarding reduced prevalence with hepatitis C treatment are still valid: A reply to Vickerman et al.. <i>Drug and Alcohol Dependence</i> , 2011, 113, 86-87.	1.6	3
58	Increasing HIV diagnoses in Australia among men who have sex with men correlated with the growing number not taking antiretroviral therapy. <i>Sexual Health</i> , 2011, 8, 304.	0.4	9
59	Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. <i>Aids</i> , 2011, 25, 2069-2078.	1.0	69
60	The burden of HIV-associated neurocognitive impairment in Australia and its estimates for the future. <i>Sexual Health</i> , 2011, 8, 541.	0.4	25
61	Timing of the Components of the HIV Life Cycle in Productively Infected CD4 ⁺ T Cells in a Population of HIV-Infected Individuals. <i>Journal of Virology</i> , 2011, 85, 10798-10805.	1.5	60
62	CD4 ⁺ T-Cell Deficiency in HIV Patients Responding to Antiretroviral Therapy Is Associated With Increased Expression of Interferon-Stimulated Genes in CD4 ⁺ T Cells. <i>Journal of Infectious Diseases</i> , 2011, 204, 1927-1935.	1.9	100
63	In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. <i>Hepatology</i> , 2010, 52, 16-24.	3.6	76
64	Simultaneous classification and feature selection via convex quadratic programming with application to HIV-associated neurocognitive disorder assessment. <i>European Journal of Operational Research</i> , 2010, 206, 470-478.	3.5	30
65	A screening algorithm for HIV-associated neurocognitive disorders. <i>HIV Medicine</i> , 2010, 11, 642-649.	1.0	48
66	The Prevalence of Sexually Transmitted Infections in Papua New Guinea: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2010, 5, e15586.	1.1	65
67	A Novel Chemokine-Receptor-5 (CCR5) Blocker, SCH532706, Has Differential Effects on CCR5+CD4 ⁺ and CCR5+CD8 ⁺ T Cell Numbers in Chronic HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 653-661.	0.5	14
68	When the presumption of innocence is not beneficial: periodic presumptive treatment for STIs and HIV in female sex workers. <i>Sexually Transmitted Infections</i> , 2010, 86, 161-162.	0.8	1
69	In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy. <i>Retrovirology</i> , 2010, 7, 83.	0.9	16
70	Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. <i>Drug and Alcohol Dependence</i> , 2010, 110, 228-233.	1.6	45
71	Minimal impact of circumcision on HIV acquisition in men who have sex with men. <i>Sexual Health</i> , 2010, 7, 463.	0.4	11
72	Evolution of CD4 ⁺ T Cell Count in HIV-1-Infected Adults Receiving Antiretroviral Therapy with Sustained Long-Term Virological Suppression. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 569-576.	0.5	10

#	ARTICLE	IF	CITATIONS
73	HIV Dynamics and Integrase Inhibitors. <i>Antiviral Chemistry and Chemotherapy</i> , 2009, 19, 157-164.	0.3	4
74	Reply:. <i>Hepatology</i> , 2009, 49, 1780-1781.	3.6	1
75	Mathematical modelling of the impact of haematopoietic stem cell-delivered gene therapy for HIV. <i>Journal of Gene Medicine</i> , 2009, 11, 1077-1086.	1.4	15
76	Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. <i>Nature Medicine</i> , 2009, 15, 285-292.	15.2	259
77	Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success. <i>Virology Journal</i> , 2009, 6, 184.	1.4	19
78	Rapidly ageing HIV epidemic among men who have sex with men in Australia. <i>Sexual Health</i> , 2009, 6, 83.	0.4	42
79	Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. <i>Hepatology</i> , 2008, 48, 1079-1086.	3.6	56
80	Virologic Determinants of Success After Structured Treatment Interruptions of Antiretrovirals in Acute HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 140-147.	0.9	38
81	Significant reduction in HIV prevalence according to male circumcision intervention in sub-Saharan Africa. <i>International Journal of Epidemiology</i> , 2008, 37, 1246-1253.	0.9	35
82	Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 140-47.	0.9	31
83	Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. <i>Aids</i> , 2007, 21, 2315-2321.	1.0	172
84	Impaired Intrahepatic Hepatitis B Virus Productivity Contributes to Low Viremia in Most HBeAg-Negative Patients. <i>Gastroenterology</i> , 2007, 133, 843-852.	0.6	178
85	The half-life of hepatitis B virions. <i>Hepatology</i> , 2006, 44, 1117-1121.	3.6	80
86	Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. <i>Journal of Gene Medicine</i> , 2005, 7, 552-564.	1.4	102
87	Dynamics of hepatitis B virus clearance in chimpanzees. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 17780-17785.	3.3	140
88	Human Immunodeficiency Virus: Quasi-Species and Drug Resistance. <i>Multiscale Modeling and Simulation</i> , 2005, 3, 300-311.	0.6	13
89	Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. <i>Immunology and Cell Biology</i> , 2003, 81, 487-495.	1.0	99
90	The effect of heterogeneity on optimal regimens in cancer chemotherapy. <i>Mathematical Biosciences</i> , 2003, 185, 73-87.	0.9	10

#	ARTICLE	IF	CITATIONS
91	The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. <i>International Journal of Epidemiology</i> , 2003, 32, 708-714.	0.9	51
92	Changing Transmission Fitness of Drug-Resistant Human Immunodeficiency Virus against a Background of Evolving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2003, 188, 1258-1258.	1.9	4
93	Discontinuation of Antiretroviral Therapy Commenced Early during the Course of Human Immunodeficiency Virus Type 1 Infection, with or without Adjunctive Vaccination. <i>Journal of Infectious Diseases</i> , 2002, 186, 634-643.	1.9	129
94	Relative Significance of Different Pathways of Immune Reconstitution in HIV Type 1 Infection as Estimated by Mathematical Modeling. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 147-159.	0.5	20
95	Kinetics of Acute Hepatitis B Virus Infection in Humans. <i>Journal of Experimental Medicine</i> , 2001, 193, 847-854.	4.2	178
96	Optimal control for a stochastic model of cancer chemotherapy. <i>Mathematical Biosciences</i> , 2000, 168, 187-200.	0.9	57
97	A model of primary HIV-1 infection. <i>Mathematical Biosciences</i> , 1998, 154, 57-85.	0.9	43
98	The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy. <i>Mathematical Medicine and Biology</i> , 1997, 14, 283-303.	0.8	20
99	Optimal drug regimens in cancer chemotherapy for single drugs that block progression through the cell cycle. <i>Mathematical Biosciences</i> , 1994, 123, 183-213.	0.9	24
100	Some optimal control problems in cancer chemotherapy with a toxicity limit. <i>Mathematical Biosciences</i> , 1990, 100, 49-67.	0.9	80
101	Optimal control for a cancer chemotherapy problem with general growth and loss functions. <i>Mathematical Biosciences</i> , 1990, 98, 273-287.	0.9	103
102	Some existence and regularity results for dual linear control problems. <i>Journal of Mathematical Analysis and Applications</i> , 1985, 112, 190-209.	0.5	2